RSS   Newsletter   Contact   Advertise with us

Immune Design appoints chief business officer

Staff writer | Seattle, Wa., USA | September 27, 2013
Immune DesignSeptember 27, 2013, Seattle, Wa., USA - Immune Design Corp., a biotechnology company, announced the appointment of Stephen R. Brady as its chief business officer.
Most recently, Mr. Brady served as Chief Business Officer for 3-V Biosciences, Inc., where he led business and operations activities, including finance, legal, corporate communications and strategic portfolio planning.

Previously, he served as Vice President of Corporate Development for Proteolix, Inc., where he was primarily responsible for corporate development and legal affairs, including the sale of the Company to Onyx Pharmaceuticals in 2009.

Prior to his tenure with Proteolix, Mr. Brady served as Senior Corporate Counsel at Lexicon Pharmaceuticals, Inc., where he served primarily in business development and legal capacities. Mr. Brady was also a Vice President with Lazard Venture Advisors, a division of Lazard Freres & Co, LLC., and an associate in the New York and San Francisco offices of Morrison & Foerster LLP.

Mr. Brady received a B.A. in English from the University of Oregon and a LL.M. from New York University School of Law.